低社会经济地位（SES）是包括癌症在内的多种疾病的死亡和免疫功能障碍的危险因素。然而，癌症的独特之处在于使用同种异体造血细胞移植（HCT）作为血液恶性肿瘤的治疗方法，将健康的造血细胞从一个人转移到另一个人。这就提出了一个问题：根据低社会经济地位评估，HCT 细胞捐献者的社会劣势是否可能会影响 HCT 接受者随后的健康结果。为了评估 SES 相关健康风险的细胞移植性，我们分析了在 125 个美国移植中心因血液恶性肿瘤接受移植的 2,005 名 HCT 接受者的健康结果，并测试了他们的结果是否随细胞捐赠者的 SES 的变化而有所不同（控制其他已知的 HCT 相关风险因素）。与来自 SES 最低四分位的捐赠者的细胞移植的受者相比，接受来自 SES 最低四分位的捐赠者的细胞移植的受者的总生存率降低了 9.7%（P = 0.001），并且 3 年内治疗相关死亡率增加了 6.6%（P = 0.008）。 SES 最高四分位数。这些结果与之前的研究一致，即社会经济劣势与免疫细胞功能和造血功能的改变有关，并且它们揭示了在细胞转移到新的宿主环境后，这些影响会出现意想不到的持续性。这些与社会经济地位相关的健康结果差异强调需要绘制健康社会决定因素所涉及的生物机制，并制定干预措施来阻止这些影响并增强 HCT 捐赠者和接受者的健康。

Low socioeconomic status (SES) is a risk factor for mortality and immune dysfunction across a wide range of diseases, including cancer. However, cancer is distinct in the use of allogeneic hematopoietic cell transplantation (HCT) as a treatment for hematologic malignancies to transfer healthy hematopoietic cells from one person to another. This raises the question of whether social disadvantage of an HCT cell donor, as assessed by low SES, might impact the subsequent health outcomes of the HCT recipient. To evaluate the cellular transplantability of SES-associated health risk, we analyzed the health outcomes of 2,005 HCT recipients who were transplanted for hematologic malignancy at 125 United States transplant centers and tested whether their outcomes differed as a function of their cell donor's SES (controlling for other known HCT-related risk factors). Recipients transplanted with cells from donors in the lowest quartile of SES experienced a 9.7% reduction in overall survival (P = 0.001) and 6.6% increase in treatment-related mortality within 3 y (P = 0.008) compared to those transplanted from donors in the highest SES quartile. These results are consistent with previous research linking socioeconomic disadvantage to altered immune cell function and hematopoiesis, and they reveal an unanticipated persistence of those effects after cells are transferred into a new host environment. These SES-related disparities in health outcomes underscore the need to map the biological mechanisms involved in the social determinants of health and develop interventions to block those effects and enhance the health of both HCT donors and recipients.